Non-clinical efficacy and PK/PD studies of golidocitinib (also named as AZD4205 or DZD4205) in xenograft model allow for increased and longer suppression of JAK1/STAT3 signaling and subsequent better anti-tumor activity as compared to ruxolitinib (Jason G. 7, 8). This evidence concerns the gene JAK1 and neoplasm.